These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18053428)

  • 1. Targets, trials, and travails in pancreas cancer.
    Izeradjene K; Hingorani SR
    J Natl Compr Canc Netw; 2007 Nov; 5(10):1042-53. PubMed ID: 18053428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic adenocarcinoma.
    Ryan DP; Hong TS; Bardeesy N
    N Engl J Med; 2014 Sep; 371(11):1039-49. PubMed ID: 25207767
    [No Abstract]   [Full Text] [Related]  

  • 3. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular mechanisms of pancreatic cancer and potential targets of treatment.
    Aho U; Zhao X; Löhr M; Andersson R
    Scand J Gastroenterol; 2007 Mar; 42(3):279-96. PubMed ID: 17354106
    [No Abstract]   [Full Text] [Related]  

  • 5. Exploiting molecular targets in pancreatic cancer.
    Wolff RA
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):139-57. PubMed ID: 12063824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
    Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
    Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New biomarkers and targets in pancreatic cancer and their application to treatment.
    Costello E; Greenhalf W; Neoptolemos JP
    Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):435-44. PubMed ID: 22733351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Responses to targeted therapies: colorectal cancer].
    Bibeau F; Frugier H; Boissière-Michot F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S74-6. PubMed ID: 19887260
    [No Abstract]   [Full Text] [Related]  

  • 10. Signaling pathways in pancreatic cancer.
    Reddy SA
    Cancer J; 2001; 7(4):274-86. PubMed ID: 11561604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of predictive markers in oncology: are phase 3 trials always required?
    Markman M
    Oncology; 2011; 81(1):1-2. PubMed ID: 21894048
    [No Abstract]   [Full Text] [Related]  

  • 12. Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.
    Ohtsubo K; Ishikawa D; Nanjo S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Yasumoto K; Gabata T; Matsui O; Ikeda H; Takamatsu Y; Iwakami S; Yano S
    JOP; 2013 Sep; 14(5):515-20. PubMed ID: 24018598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting signal transduction in pancreatic cancer treatment.
    Yeh JJ; Der CJ
    Expert Opin Ther Targets; 2007 May; 11(5):673-94. PubMed ID: 17465725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic modulation of k-ras signaling in colorectal cancer.
    Krens LL; Baas JM; Gelderblom H; Guchelaar HJ
    Drug Discov Today; 2010 Jul; 15(13-14):502-16. PubMed ID: 20594936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
    Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
    Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic cancer research matures.
    Nelson NJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1432-4. PubMed ID: 17895469
    [No Abstract]   [Full Text] [Related]  

  • 18. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
    Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
    Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing methods for the diagnosis of pancreatic cancer.
    Brugge WR
    J Clin Gastroenterol; 2007; 41(10):869-70. PubMed ID: 18090153
    [No Abstract]   [Full Text] [Related]  

  • 20. Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
    Samore WR; Gondi CS
    Expert Opin Investig Drugs; 2014 Jun; 23(6):793-807. PubMed ID: 24673265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.